Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognostics)
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognostic

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognostic)

Cancer biomarkers are biomolecules that specify the existence of cancer or cancerous cells in the body. These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer. These molecules are densely distributed in tissues, urine, serum, blood, and other body fluids. Their expression levels serve as the basis or indication of any abnormal process or a disease. The market size of the global cancer biomarkers market was valued at $6,521 million in 2015 and is estimated to grow at a CAGR of 13% over the forecast period to reach $15,737 million in 2022. Market growth is attributed to the increasing incidences of cancers such as lung cancer, breast cancer, and prostate cancer among others coupled with growing importance of biological and targeted drug therapies and technological advancements in the field of cancer treatment. However, unregulated government laws and reimbursement policies; as well as high cost of drug development and threat of failure are anticipated to have an adverse effect on the market growth. Nevertheless, advancement in cancer drugs research and significant unmet need in cancer diagnosis are estimated to overshadow these restraints.

The global cancer biomarkers market is segmented based on profiling technology, biomolecules, cancer type, application, and geography. By profiling technology, the market is segmented into omic technologies, imaging technologies, immunoassays and cytogenetics based tests. Based on biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers. Amongst these, genetic biomarkers are widely used in the market owing to better diagnostic and therapeutic usage as compared to protein and glycoprotein biomarkers.

The various cancer types include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Amongst these, lung cancer is the major cancer type where biomarkers are being used for detection. Owing to high tobacco consumption and smoking, lung cancer has increased at an alarming rate. CEACAM-5/CD66e, Cytokeratin 19, EGF R/ErbB1, Enolase 2/Neuron-specific Enolase, Lactate Dehydrogenase A/LDHA, Lactate Dehydrogenase B/LDHB, Napsin A and PDGFRL are some of the major cancer biomarkers used for lung cancer detection.

Geographically, North America is the leading revenue generating region, due to high incidence rate of cancer, growth in awareness towards cancer and higher cancer biomarker testing. Asia-Pacific is growing at the fastest CAGR due to rise in awareness, increased disposable income, and affordability for advanced cancer treatments. Companies have adopted collaboration and partnership as their key development strategies. Increase in focus on collaboration and partnership is mainly for the development of innovative technologies in the field of cancer biomarkers. In May 2016, Roche received an approval by FDA for its first anti-PD-L1 cancer immunotherapy namely Tecentriq (atezolizumab), thereby expanding its product portfolio.

KEY BENEFITS FOR STAKEHOLDERS:

- The drivers, restraints, and opportunities in the global cancer biomarkers market are expected to help in understanding the market behavior better.
- The market estimations are a result of high-end analysis of the key market segments for the period of 2014–2022
- Projections in the report are made by analyzing the current market trends and future market potential for the forecast period in terms of value. The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market.
- The country level analysis has been done to provide micro market sizing of cancer biomarkers in different regions.
- The five forces model gives an in-depth analysis of bargaining power of buyers and suppliers, threats of new entrants & substitutes, and competition amongst the key market players.

https://www.bioportfolio.co.uk/product/103374
KEY MARKET SEGMENTS:

By Profiling Technologies

Omic Technologies

Imaging Technologies

Imunoassays

Cytogenetics Based Tests

Biomarkers

Protein Biomarkers

Glycoprotein Biomarkers

By Cancer Types

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Other Cancers

By Biomolecules

Genetic Biomarkers

Protein Biomarkers

Glycoprotein Biomarkers

By Cancer Types

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Other Cancers

By Application

Diagnostics

Drug Discovery and Development

Prognostics

Risk Assessment

Others

By Geography

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Russia

Rest of Europe

Asia-Pacific

Japan

India

China

Australia

Rest of Asia-Pacific

Rest of Latin America

Brazil

Rest of Latin America

Rest of Asia-Pacific

Brazil

Saudi Arabia

UAE

Rest of Latin America

Key players operating in the cancer biomarkers market include:

F. Hoffmann-La Roche Ltd.

Abbott Laboratories

GlaxoSmithKline plc

Novartis AG

Merck & Co., Inc.

Bristol-Myers Squibb

Eli Lilly and Company

Pfizer, Inc.

Qiagen N.V.

Genomic Health, Inc.

*Other players in the value chain include:

bioMérieux

Astellas Pharma Inc.

Myriad Genetics

Epigenomics

Radient Pharmaceuticals

*Profiles of these companies are not included. However, the same will be included as per the request.

Additional Details

Publisher: Allied Market Research
Reference: LI 161443
Number of Pages: 172
Report Format: PDF
Publisher Information:
CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Biomarker diagnosis vs. conventional diagnosis
3.3 Key findings

3.3.1 Drivers

3.3.1.1 Rise in incidence and prevalence of various cancer types
3.3.1.2 Growth in importance of biological and targeted drug therapies
3.3.1.3 Expiration of key patents and biosimilars impact
3.3.1.4 Increase in acquisitions and collaborations
3.3.1.5 Technological advancements
3.3.1.6 Accuracy and reliability
3.3.1.7 Rise in investment from government, public, and private sectors
3.3.1.8 Increase in clinical trials
3.3.1.9 Growth in popularity of personalized medicine and companion diagnostics

3.3.2 Restraints

3.3.2.1 High cost of drug development and threat of failure
3.3.2.2 Unregulated government regulation and reimbursement policies
3.3.2.3 Adverse effects of cancer drug therapy

3.3 Opportunities

3.3.3.1 Advancement of cancer drugs research
3.3.3.2 Increased focus towards advanced treatment protocols
3.3.3.3 Significant unmet need in cancer diagnosis
3.3.3.4 Increased awareness to reduce healthcare costs
3.3.3.5 Opportunities in emerging economies

3.3.4 Top investment pockets
3.3.5 Top winning strategies

3.4 Porters five forces analysis

3.4.1 High bargaining power of suppliers
3.4.2 Low bargaining power of buyers
3.4.3 High threat from substitutes
3.4.4 Low threat of new entrants
3.4.5 High intensity of competitive rivalry

3.5 Top player positioning, 2015
3.6 Patent analysis

3.6.1 U.S. patent analysis by market participant
3.6.2 Europe patent analysis by market participant
3.6.3 China patent analysis by market participant
3.6.4 Canada patent analysis by market participant
3.6.5 Japan patent analysis by market participant
3.6.6 Other countries patent analysis by market participant

3.7 Clinical trials

CHAPTER 4 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022

4.1 Overview

4.1.1 Market size and forecast

4.1 Omic technologies

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.1.4 Genomics

4.1.4.1 Market size and forecast
4.1.4.2 Next-generation sequencing (NGS)
4.1.4.3 Microarray
4.1.4.4 Polymerase chain reaction (PCR)

4.1.5 Proteomics

4.1.5.1 Market size and forecast
4.1.5.2 Mass spectrometry
4.1.5.3 3D gel electrophoresis
4.1.5.4 Protein microarray technology
4.1.5.5 Antibody array technology
4.1.5.6 Peptide array technology

4.1.6 Other omic technologies
4.1.6.1 Market size and forecast
4.1.6.2 Metabolomics
4.1.6.3 Glycomics

4.2 Imaging technologies
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Magnetic resonance imaging
4.2.5 Positron emission tomography
4.2.6 Computed tomography
4.2.7 Mammography
4.2.8 Ultrasound

4.3 Immunoassays
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Immunohistochemistry tests
4.3.5 Enzyme-linked immunosorbent assay
4.3.6 Flow cytometry

4.4 Cytogenetics-based tests
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 In situ hybridization
4.4.5 Others (karyotyping, amplichip, and in vitro diagnostic multivariate index assays [IVDMIA])

CHAPTER 5 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE (2014-2022)

5.1 Overview
5.1.1 Market size and forecast
5.2 Genetic biomarkers
5.2.1 Market size and forecast
5.3 Protein biomarkers
5.3.1 Market size and forecast
5.4 Glyco-biomarkers
5.4.1 Market size and forecast
CHAPTER 6 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 Lung cancer

6.2.1 Market size and forecast

6.3 Breast cancer

6.3.1 Market size and forecast

6.4 Colorectal cancer

6.4.1 Market size and forecast

6.5 Prostate cancer

6.5.1 Market size and forecast

6.1 Stomach cancer

6.1.1 Market size and forecast

6.2 Others

6.2.1 Market size and forecast

CHAPTER 7 CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022

7.1 Overview

7.1.1 Market size and forecast

7.2 Diagnostics

7.2.1 Market size and forecast

7.3 Drug discovery and development

7.3.1 Market size and forecast

7.4 Prognostics

7.4.1 Market size and forecast

7.5 Risk assessment

7.5.1 Market size and forecast

7.6 Others (personalized medicine, surrogate endpoints, recurrence, and therapeutics)

7.6.1 Market size and forecast
CHAPTER 8 CANCER BIOMARKERS MARKET BY GEOGRAPHY, 2014-2022

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key market trends
8.2.2 Growth factors and opportunities
8.2.3 Market size and forecast

8.2.3.1 U.S.: market size and forecast
8.2.3.2 Canada: market size and forecast
8.2.3.3 Mexico: market size and forecast

8.3 Europe

8.3.1 Key market trends
8.3.2 Growth factors and opportunities
8.3.3 Market size and forecast

8.3.3.1 Germany: market size and forecast
8.3.3.2 UK: market size and forecast
8.3.3.3 France: market size and forecast
8.3.3.4 Italy: market size and forecast
8.3.3.5 Russia: market size and forecast
8.3.3.6 Rest of Europe: market size and forecast

8.4 Asia-Pacific

8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast

8.4.3.1 Japan: market size and forecast
8.4.3.2 China: market size and forecast
8.4.3.3 India: market size and forecast
8.4.3.4 Australia: market size and forecast
8.4.3.5 Rest of Asia-Pacific: market size and forecast

8.5 LAMEA (Latin America, Middle East, and Africa)

8.5.1 Key market trends
8.5.2 Key growth factors and opportunities

8.5.2.1 Brazil: market size and forecast
8.5.2.2 Saudi Arabia: market size and forecast
8.5.2.3 UAE: market size and forecast
8.5.2.4 Rest of LAMEA: market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 F. Hoffmann-La Roche Ltd.

9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and developments

9.2 Abbott Laboratories
9.2.1 Company overview
9.2.2 Company Snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategies & developments

9.3 GlaxoSmithKline plc
9.3.1 Company overview
9.3.2 Operating business segments
9.3.3 Business performance
9.3.4 Key strategies and developments

9.4 Novartis AG
9.4.1 Company overview
9.4.2 Operating business segments
9.4.3 Business performance
9.4.4 Key strategies and developments

9.5 Merck & Co., Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Business performance
9.5.5 Key strategies and developments

9.6 Bristol-Myers Squibb
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Key strategies and developments

9.7 Eli Lilly and Company
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategies and developments

9.8 Pfizer, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategies and developments
9.9 Qiagen N.V.

9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Key strategy move and development

9.10 Genomic Health, Inc.

9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Business performance
9.10.4 Key strategies and developments

List of Figures

FIG. 1 CANCER BIOMARKERS MARKET: SEGMENTATION
FIG. 2 TOP IMPACTING FACTORS: CANCER BIOMARKERS MARKET, 2015-2022
FIG. 3 PERCENTAGE (%) OF NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 4 TOP INVESTMENT POCKETS: CANCER BIOMARKERS, 2015-2022
FIG. 5 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION
FIG. 6 TOP WINNING STRATEGIES: NATURE & TYPE
FIG. 7 TYPES OF STRATEGIES DISTRIBUTION
FIG. 8 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIG. 9 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIG. 10 PORTERS FIVE FORCES ANALYSIS
FIG. 11 TOP PLAYER POSITIONING, 2015
FIG. 12 PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2016
FIG. 13 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 14 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 15 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 16 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 17 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 18 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 19 U.S.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 20 CANADA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 21 MEXICO: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 22 GERMANY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 24 FRANCE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 25 ITALY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 26 RUSSIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 27 REST OF EUROPE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 28 JAPAN: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 29 CHINA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 30 INDIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 31 AUSTRALIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 32 REST OF ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 33 BRAZIL: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 34 SAUDI ARABIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 35 UAE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 36 REST OF LAMEA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 37 ROCHE: NET SALES, 2013-2015 ($MILLION)
FIG. 38 ROCHE: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 39 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 40 ROCHE: STRATEGY SHARE, 2014-2016 (%)
FIG. 41 ABBOTT: NET SALES, 2013-2015 ($MILLION)
FIG. 42 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 43 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 44 ABBOTT: STRATEGY SHARE, 2014-2016 (%)
FIG. 45 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 46 GSK: NET SALES, 2013-2015 ($MILLION)
FIG. 47 GSK: REVENUE, BY SEGMENT, 2015 (%)
FIG. 48 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 49 GSK: STRATEGY SHARE, 2014-2016 (%)
FIG. 50 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
FIG. 51 NOVARTIS: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 52 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 53 NOVARTIS: STRATEGY SHARE, 2014-2016 (%)
FIG. 54 MERCK: NET SALES, 2013-2015 ($MILLION)
FIG. 55 MERCK: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 56 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 57 MERCK: STRATEGY SHARE, 2014-2016 (%)
FIG. 58 BRISTOL-MYSERS SQUIBB: NET SALES, 2013-2015 ($MILLION)
FIG. 59 BRISTOL-MYSERS SQUIBB, REVENUE, BY GEOGRAPHY, 2015(%)
FIG. 60 BRISTOL-MYSERS SQUIBB: STRATEGY SHARE, 2014-2016 (%)
FIG. 61 ELI LILLY: NET SALES, 2013-2015, ($MILLION)
FIG. 62 ELI LILLY: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 63 ELI LILLY: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 64 ELI LILLY: STRATEGY SHARE, 2014-2016 (%)
FIG. 65 PFIZER, INC.: NET SALES, 2013-2015, ($MILLION)
FIG. 66 PFIZER, INC.: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 67 PFIZER, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 68 PFIZER, INC.: STRATEGY SHARE, 2014-2016 (%)
FIG. 69 QIAGEN: NET SALES, 2013-2015, ($MILLION)
FIG. 70 QIAGEN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 71 QIAGEN: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 72 QIAGEN: STRATEGY SHARE, 2014-2016 (%)
FIG. 73 GENOMIC HEALTH: NET SALES, 2013-2015 ($MILLION)
FIG. 74 GENOMIC HEALTH: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 75 GENOMIC HEALTH: STRATEGY SHARE, 2014-2016 (%)

List of Tables

TABLE 1 CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 2 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES (2012)
TABLE 3 REVENUE GENERATION OF BIOLOGICAL AND TARGETED DRUGS IN 2013 ($MILLION)
TABLE 4 KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 5 COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
TABLE 6 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE, CANADA, CHINA, JAPAN, AND OTHERS, 2013 THROUGH 2016
TABLE 7 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 8 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 9 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 10 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 11 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 12 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 13 CLINICAL TRIALS: CANCER BIOMARKERS
TABLE 14 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 15 WORLD OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 16 WORLD OMICS TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 GLOBAL GENOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 1 GLOBAL PROTEOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 2</td>
<td>Global Other Omics Technology Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 3</td>
<td>Global Imaging Technology Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 4</td>
<td>Global Imaging Technology Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 5</td>
<td>Global Immunoassays Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 6</td>
<td>Global Immunoassays Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 7</td>
<td>Global Cytogenetics-Based Tests Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 8</td>
<td>Global Cytogenetics-Based Tests Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 9</td>
<td>Global Cancer Biomarkers Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 10</td>
<td>Global Cancer Biomarkers Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 11</td>
<td>Global Protein Biomarkers Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 12</td>
<td>Global Glyco-Biomarkers Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 13</td>
<td>Cancer Biomarkers Market, by Cancer Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 14</td>
<td>Global Cancer Biomarkers for Lung Cancer, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 15</td>
<td>Global Cancer Biomarkers for Breast Cancer, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 16</td>
<td>Global Cancer Biomarkers for Colorectal Cancer Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 17</td>
<td>Global Cancer Biomarkers for Prostate Cancer Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 18</td>
<td>Global Cancer Biomarkers for Stomach Cancer Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 19</td>
<td>Global Cancer Biomarkers for Other Cancers, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 20</td>
<td>Cancer Biomarkers Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 21</td>
<td>Diagnostics Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 22</td>
<td>Drug Discovery and Development Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 23</td>
<td>Prognostics Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 24</td>
<td>Risk Assessment Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 25</td>
<td>Others Market, by Geography, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 26</td>
<td>Cancer Biomarkers Market, by Geography, 2014-2020 ($Million)</td>
</tr>
<tr>
<td>Table 27</td>
<td>North America Cancer Biomarkers Market, by Profiling Technology, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 28</td>
<td>North America Cancer Biomarkers Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 29</td>
<td>North America Cancer Biomarkers Market, by Cancer Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 30</td>
<td>North America Cancer Biomarkers Market, by Application, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 31</td>
<td>North American Cancer Biomarkers Market, by Country, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 32</td>
<td>European Cancer Biomarkers Market, by Profiling Technology, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 33</td>
<td>European Cancer Biomarkers Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 34</td>
<td>European Cancer Biomarkers Market, by Cancer Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 35</td>
<td>European Cancer Biomarkers Market, by Application, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 36</td>
<td>European Cancer Biomarkers Market, by Country, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 37</td>
<td>Asia-Pacific Cancer Biomarkers Market, by Profiling Technology, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 38</td>
<td>Asia-Pacific Cancer Biomarkers Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 39</td>
<td>Asia-Pacific Cancer Biomarkers Market, by Cancer Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 40</td>
<td>Asia-Pacific Cancer Biomarkers Market, by Application, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 41</td>
<td>Asia-Pacific Cancer Biomarkers Market, by Country, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 42</td>
<td>Lamea Cancer Biomarkers Market, by Profiling Technology, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 43</td>
<td>Lamea Cancer Biomarkers Market, by Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 44</td>
<td>Lamea Cancer Biomarkers Market, by Cancer Type, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 45</td>
<td>Lamea Cancer Biomarkers Market, by Application, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 46</td>
<td>Lamea Cancer Biomarkers Market, by Country, 2014-2022 ($Million)</td>
</tr>
<tr>
<td>Table 47</td>
<td>Roche: Company Snapshot</td>
</tr>
<tr>
<td>Table 48</td>
<td>Abbott: Company Snapshot</td>
</tr>
<tr>
<td>Table 49</td>
<td>Abbott: Operating Segments</td>
</tr>
<tr>
<td>Table 50</td>
<td>Gsk: Company Snapshot</td>
</tr>
<tr>
<td>Table 51</td>
<td>Gsk: Operating Segments</td>
</tr>
<tr>
<td>Table 52</td>
<td>Novartis: Company Snapshot</td>
</tr>
<tr>
<td>Table 53</td>
<td>Novartis: Operating Segments</td>
</tr>
</tbody>
</table>
TABLE 54 MERCK: COMPANY SNAPSHOT
TABLE 55 MERCK: PRODUCT CATEGORIES
TABLE 56 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 58 ELI LILLY: OPERATING SEGMENTS
TABLE 59 PFIZER, INC.: COMPANY SNAPSHOT
TABLE 60 PFIZER, INC.: OPERATING SEGMENTS
TABLE 61 QIAGEN: COMPANY SNAPSHOT
TABLE 62 GENOMIC HEALTH: COMPANY SNAPSHOT
How to Buy...

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognostic [Report Updated: 01-12-2016]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/103374

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: .....................................................................................................................
Job Title: .............................................................................................................................
Your Email: ..........................................................................................................................
Your Contact Phone: ..........................................................................................................
Company Name: .................................................................................................................
Address: ...............................................................................................................................
Post/Zip Code: .....................................................................................................................
Country: ...............................................................................................................................
P.O. Number: .......................................................................................................................
Any Other Instructions: .........................................................................................................

Pricing Options: (please tick one)
○ £5370 | Single User Price
○ £5910 | Five User License Price
○ £7800 | Enterprise License Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ........................................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.